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Abstract: Objective
The Val allele of the Val158Met single-nucleotide polymorphism of the catechol-o-
methyltransferase gene (COMT) results in faster metabolism and reduced
bioavailability of dopamine (DA). Among persons living with HIV (PLWH), Val carriers
display neurocognitive deficits relative to Met carriers, presumably due to exacerbation
of HIV-related depletion of DA. COMT may also impact neurocognition by modulating
cardiometabolic function, which is often dysregulated among PLWH. We examined the
interaction of COMT, cardiometabolic risk, and nadir CD4 on NCI among HIV+ men.
Methods
329 HIV+ men underwent COMT genotyping and neurocognitive and neuromedical
assessments. Cohort-standardized z-scores for body mass index, systolic blood
pressure, glucose, triglycerides, and high-density lipoprotein cholesterol were
averaged to derive a cardiometabolic risk score (CMRS). Neurocognitive impairment
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
(NCI) was defined as demographically-adjusted global deficit score≥0.5. Logistic
regression modelled NCI as a function of COMT, CMRS, and their interaction,
covarying for estimated premorbid function, race/ethnicity, and HIV-specific
characteristics. Follow-up analysis included the 3-way interaction of COMT, CMRS,
and nadir CD4.
Results
Genotypes were 81 Met/Met, 147 Val/Met, and 101 Val/Val. COMT interacted with
CMRS (p=0.02) such that higher CMRS increased risk of NCI among Val/Val
(OR=2.13, p<.01), but not Val/Met (OR=0.93, p>.05) or Met/Met (OR=0.92, p>.05)
carriers. Among Val/Val, nadir CD4 moderated the effect of CMRS (p<.01) such that
higher CMRS increased likelihood of NCI only when nadir CD4<180.
Discussion
Results suggest a tripartite model by which genetically-driven low DA reserve,
cardiometabolic dysfunction, and historical immunosuppression synergistically
enhance risk of NCI among HIV+ men, possibly due to neuroinflammation and
oxidative stress.
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Dear Dr. Volberding, 
We thank you for the opportunity to submit a revised version of our manuscript. We have 
addressed all the editorial and reviewer comments (in bold) and have provided detailed responses 
below. We have also used red text to indicate sections that have been changed within the 
manuscript itself. We hope that you will find the revised manuscript substantively improved. 
 
Reviewer #1:  
In this manuscript, Saloner et al. investigated the interplay between COMT SNPs, 
cardiometabolic risk factors and nadir CD4 as risk factors for NCI in HIV-infected men. 
They observed that (a) higher cardiometabolic risk score increased the risk of NCI only 
among Val/Val carriers and that (b) this effect was evident only when nadir CD4 was <180 
cells/mmc. These findings were confirmed also in the subgroup of patients with HIV-RNA 
<50 copies/mL. Taken together, these observations seem to suggest that genetically-driven 
low DA reserve, cardiometabolic dysfunction, and history of immunosuppression 
synergistically enhance risk of NCI and that antiretroviral treatment alone might not 
completely restore cognitive function. 
The paper is well written. The results of the study are interesting and of relevance; 
moreover, data are accurately described and discussed. Limitation are adequately 
acknowledged. 
Some minor issues should be addressed before publication: 
1. The title should specify that results are obtained in a male population. For example, 
an alternative title could be: "COMT Val158Met Polymorphism, Cardiometabolic Risk, 
and Nadir CD4 Synergistically Increase Risk for Neurocognitive Impairment in HIV-
infected Men". 
Response: We appreciate the suggestion to increase the specificity of our title, so we have 
changed it to COMT Val158Met Polymorphism, Cardiometabolic Risk, and Nadir CD4 
Synergistically Increase Risk for Neurocognitive Impairment in Men Living with HIV. 
2. Abstract, results: Please report also percentages for the three genotypes of the 
COMT gene. 
Response to Reviewers
Response: We have now added percentages for COMT genotypes in the Abstract: “Genotypes 
were 81 (24.6%) Met/Met, 147 (44.7%) Val/Met, and 101 (30.7%) Val/Val.” 
3. Page 5, first paragraph: correct type error "verus" to "versus" 
Response: Thank you for identifying this typographical error, we have now corrected it. 
4. Table 1. Plasma and CSF viral load should be expressed as copies/mL and not 
cells/mL 
Response: We have made the suggested change and plasma/CSF viral load is now expressed as 
copies/ml. 
5. Table 2. I suppose that results are expressed as mean (SD) except for glucose 
(median - IQR?) and NCI (n, %). Please specify in the notes. 
Response: Yes, glucose is expressed in terms of median [IQR] and NCI as N (%). We have now 
clarified this in the notes section of Table 2. 
6. In my opinion, Table 3 is unclear: 
a. I suppose that bold variables are statistically significant variables: this should be 
specified in the notes. 
Response: We have now specified in the notes section of Table 3 that “bolded predictors are 
significant at p<.05.”  
b. I don't understand the variables "CMRS x Met/Met" and "CMRS x Val/Met". This 
result is not commented in the text. 
Response: We apologize for the confusion. We have incorporated the results of these parameters 
into the main manuscript in order to enhance the clarity of our analyses (page 12).  
Given that COMT genotype is a categorical variable with three levels, our regression analyses 
necessitate that we create two COMT parameters in order to capture the full effect of COMT on 
NCI. In order to accomplish this, we used the widely-employed technique of reference coding 
(West, Aiken, & Krull, 1996). We coded the high enzymatic activity Val/Val group as the 
reference level, which resulted in two COMT regression parameters, “Met/Met” and “Val/Met”. 
As we mention in the Table 2 notes, the Met/Met and Val/Met parameters represent the change 
in likelihood of NCI when comparing the Met/Met and Val/Met groups, respectively, to the 
Val/Val reference group.  
The same principles apply when generating regression parameters that represent interaction 
effects between a three-level categorical variable (i.e., COMT) and a continuous variable (i.e., 
CMRS; West et al., 1996). Thus, the “CMRS x Met/Met” parameter reflects how the effect of 
CMRS on NCI changes when shifting from the Val/Val reference group to the Met/Met group. 
Similarly, the “CMRS x Val/Met” parameter reflects how the effect of CMRS on NCI changes 
when shifting from the Val/Val reference group to the Val/Met group.  
West, S. G., Aiken, L. S., & Krull, J. L. (1996). Experimental personality designs: analyzing 
categorical by continuous variable interactions. J Pers, 64(1), 1-48. 
c. I suppose that the variable "detectable plasma" refers to "detectable plasma viral 
load": this should be specified. 
Response: We have now changed “detectable plasma” to “detectable plasma viral load.” 
d. Notes "f-g" are not correct, note h is lacking. 
Response: Thank you for noticing this error. We have corrected the superscripts in Table 3. 
e. Why other variables that have been associated with NCI in many other studies (such 
as age, education, AIDS diagnosis, substance use, BDI score and CSF viral load in the 
subgroup of patients with an available sample) are not considered in the multivariate 
model? 
Response: We agree that it is important to consider the possible effects of additional factors that 
may impact NCI, particularly in the context of HIV. Our rationale for covariate selection is 
described in the Statistical Analyses section (page 10). In order to account for variables that may 
potentially confound the effects of COMT on NCI, we selected covariates based on variables that 
significantly differed across COMT groups (i.e., WRAT and race/ethnicity). Age and education 
adjustments are also built into the neuropsychological test T-scores on which the cognitive 
outcomes are based. Additionally, because our study is in the context of HIV-infection, we 
included standard indicators of HIV disease severity that have been consistently linked to 
neurocognition in the modern era of antiretroviral therapy (i.e., nadir/current CD4 counts, 
antiretroviral therapy use, plasma viral load). We did not include AIDS diagnoses or CSF viral 
load as covariates because they are highly collinear (ps <.0001) with nadir/current CD4 count 
and plasma viral load, respectively, and we did not have CSF viral loads on all participants. For 
non-HIV-specific variables, BDI scores, lifetime substance use diagnoses, age, and education did 
not differ across COMT groups and were therefore not considered in our multivariable models.  
7. In the abstract, the authors report that "higher CMRS increased risk of NCI among 
Val/Val (OR=2.13, p<.01), but not Val/Met (OR=0.93, p>.05) or Met/Met (OR=0.92, p>.05) 
carriers". However, these results (OR and p values) are not reported nor in the results 
section of the main text neither in table 3 or figure 1 
Response: Per this recommendation, we now include these results in the main text (page 13). 
These results are also included in the figure caption for Figure 1.  
8. Among the limitations, it should be mentioned also the cross sectional design of the 
study. 
Response: We have now acknowledged the cross-sectional design of the study as a limitation 
(page 17): “…the cross-sectional and associative nature of our data prevent us from drawing 
causal inferences, especially about the relationship between NCI and CMRS in the context of 
genetic and HIV disease history predictors.”  
  
Reviewer #2:  
The manuscript entitled "COMT Val158Met Polymorphism, Cardiometabolic Risk, and 
Nadir CD4 Synergistically Increase Risk for HIV-associated Neurocognitive Impairment" 
approaches an interesting topic in HIV infection, which is the search of correlates that help 
understand the appearance of HIV-associated neurocognitive impairment. Specifically, this 
work focuses on the investigation of a genetic marker, the COMT Val158Met 
polymorphism, which is analyzed in combination with environmental/medical factors, such 
as the cardiometabolic status and the nadir CD4 count. Authors find explaining 
interactions among them that show connections with neurocognitive impairment at 
different levels. The results emphasize the relevance of considering both genetic and 
environmental factors in the assessment of risk/protective factors of HIV-associated 
neurocognitive dysfunction. Study data appear to be analyzed adequately and most 
information properly presented. The manuscript could be accepted for publication, 
although some changes should be applied before in the text. 
Specific comments: 
Abstract 
1. Abbreviation of neurocognitive impairment (NCI) is not correctly presented. 
Response: We have corrected this in the Abstract accordingly.  
2. Percentages should be added to frequencies of allele profiles. 
Response: We have now added percentages to complement COMT group sample sizes.  
Introduction 
3. Citations for prevalence of NCI should be optimized. References 1 and 2 appear to be 
overlapped. Reference 3 is not a work focused on NCI prevalence. I recommend to provide 
representative studies that investigate specifically prevalence or widely frequency of NCI. 
Response: We have replaced References 2 and 3 with a more representative study examining the 
prevalence of NCI/HAND in the Multicenter AIDS Cohort Study (MACS; Sacktor et al., 2016). 
Sacktor, N., Skolasky, R. L., Seaberg, E., Munro, C., Becker, J. T., Martin, E., . . . Miller, E. 
(2016). Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS 
Cohort Study. Neurology, 86(4), 334-340. doi:10.1212/wnl.0000000000002277 
4. There are some prior works that demonstrated the role of nadir CD4 cell count as a 
predictor of HIV-associated NCI previously to reference 41. 
Response: We have augmented the Introduction (page 6) with the following references that 
provide earlier documentation of the relationship between nadir CD4 and HIV-associated NCI.  
Robertson, K. R., Smurzynski, M., Parsons, T. D., Wu, K., Bosch, R. J., Wu, J., . . . Ellis, R. J. 
(2007). The prevalence and incidence of neurocognitive impairment in the HAART era. 
Aids, 21(14), 1915-1921. doi:10.1097/QAD.0b013e32828e4e27 
Tozzi, V., Balestra, P., Lorenzini, P., Bellagamba, R., Galgani, S., Corpolongo, A., . . . Narciso, 
P. (2005). Prevalence and risk factors for human immunodeficiency virus-associated 
neurocognitive impairment, 1996 to 2002: Results from an urban observational cohort. J 
Neurovirol, 11(3), 265-273. doi:10.1080/13550280590952790 
Methods 
5. GDS is chosen as method for determination of NCI, however, no discussion or 
justification about this decision is provided. Why was not the Frascati proposal used for 
this establishment? In fact, the second reference cited when GDS is presented recommends 
clinical rating classification as a more sensitive method to detect subtle forms of 
impairment. 
Response: We appreciate the comment and have expanded our Methods (pages 9 and 10) to 
provide a rationale for selecting the GDS approach to classifying NCI. As the Reviewer points 
out, there are some subtle differences between the clinical ratings (CR) approach, which aligns 
with the Frascati criteria, and the GDS approach. Both approaches have been advanced by our 
co-author Dr. Robert Heaton, who was also part of the Frascati panel. The second reference 
cited, Blackstone et al. (2012), is a prior work from our group that established that the GDS is a 
more conservative method than CR for establishing NCI, yet also virtually ensures that the CR-
based criterion for NCI is met (<1% of individuals were impaired by the GDS method and not 
the CR method). This GDS approach has been widely employed in neuroHIV research, in part 
because the process of computing a GDS and applying the 0.5 impairment cut-point is more 
readily accomplished and digestible than using the CR algorithm (see appendix of (Woods et al., 
2004)), which could be subject to computational errors and can subsequently lead to inflated 
discrepancies between the GDS and CR (Saloner & Cysique, 2017). Furthermore, the complex  
Woods et al. (2004) algorithm is applied inconsistently (or not at all), particularly regarding how 
one applies a 1 SD cutoff for ability domains with variable numbers of component tests. As 
Blackstone et al. note, without an independent “gold-standard” indicator of HIV-associated NCI, 
we cannot claim that the GDS under-classifies NCI or that the CR approach over-classifies NCI. 
Rather, we acknowledge that both approaches demonstrate strong construct validity because they 
both relate to greater HIV disease severity and functional deficits, with the GDS having an added 
benefit of being more easily replicated by other research groups.  
6. Reference for BDI should be added to text. 
Response: The BDI is now referenced in the text (page 10).  
Results 
7. Effect size analyses by Cohen's d are presented in Statistical Analyses but later in Results 
there is only a value in reference to them. Further information about the results from those 
useful complementary tests should be provided. 
Response: We have modified the Statistical Analyses section (page 10) to clarify that Cohen’s d 
statistics are presented only for statistically significant pair-wise differences. Our analyses 
examining COMT group differences (Tables 1 and 2) revealed only two statistically significant 
pairwise differences for continuous outcomes that can be used to generate a Cohen’s d statistic 
(i.e., WRAT scores: Met/Met vs. Val/Val [d=0.40; p=.007]; diastolic blood pressure: Met/Met 
vs. Val/Met [d=0.37; p=0.02]). These two Cohen’s d estimates are presented in the Results (page 
12).  
8. There were relevant differences in the demographic characteristics of the sample, 
specifically in premorbid intelligence and ethnicity/race. Was any statistical method 
applied to adjust or correct the weight of those variables in the study outcomes? 
Response: As the Reviewer notes, COMT groups differed with respect to race/ethnicity and  
estimated premorbid verbal IQ, as measured by the WRAT. In order to account for these group 
differences, we included WRAT scores and race/ethnicity as covariates in our multivariable 
logistic regression models (see Table 3). We have now reiterated in the results section (page 12) 
that we included relevant covariates in our regression models in order to assure the readers that 
we considered potential confounding factors.  
9. Citation of Table 1 in text is linked to a Cohen's d result, but no information about effect 
sizes is provided in that table. 
Response: We apologize for the confusion. We did not intend to imply that Cohen’s d results 
would be displayed in Table 1. As we describe in our response to item 15 (below), we have 
modified the Results section (page 11) to properly present Table 1 in the text.   
Discussion 
10. The finding about a specific nadir cutoff revealing differences for NCI is really 
interesting (<180 cells/mm3). Previous published works have found certainly similar values 
when investigating the development of HIV-associated NCI. Examples are Ellis et al, 2011 
and Muñoz-Moreno et al, 2014. Discussion about potential connections with those other 
findings should be incorporated in text. 
Response: The Discussion has been expanded to include a comparison of our findings to the Ellis 
and Muñoz-Moreno articles (page 16). In addition to our study, these articles provide evidence 
that lower nadir CD4 not only increases the probability of NCI as an independent factor, but also 
that severe immunosuppression may reflect enhanced vulnerability to the detrimental 
neurocognitive effects of other clinically-relevant factors. Interestingly, Muñoz-Moreno et al. 
identified a nadir CD4 value of 225, which is fairly similar to our threshold of 180, as a relevant 
cutoff for optimizing the prediction of NCI in the context of other disease and treatment 
characteristics.  
11. It is mentioned that authors' group has previously reported better executive functioning 
in Met/Met men with HIV infection compared to Val-carriers, but no citation is provided. 
Response: We apologize for the oversight. The citation in question is now provided: 
Bousman, C. A., Cherner, M., Glatt, S. J., Atkinson, J. H., Grant, I., Tsuang, M. T., & Everall, I. 
P. (2010). Impact of COMT Val158Met on executive functioning in the context of HIV 
and methamphetamine. Neurobehav HIV Med, 2010, 1-11. doi:10.2147/nbhiv.S8245 
12. The fourth limitation presented appears to be very interesting. I encourage the authors 
to offer a more extended discussion on that point, rather than stating it as a limitation, 
actually. I would suggest the same for limitation 5 since I do believe that the selection of the 
method for cardiometabolic assessment was really appropriate. 
Response: Per this recommendation, our discussion on “omics” analyses is no longer explicitly 
described as a limitation. Rather, we have expanded the Discussion (page 18) to note how the 
complexity and richness of DA-related biological data is well-suited to an “omics” approach that 
considers how multi-level genetic clusters can improve understanding of HIV-related 
neuropathogenesis. 
We have also removed limitation 5. Given that we already provide a detailed discussion of the 
merits of our cardiometabolic assessment on page 15, we have not provided any additional 
commentary on our method of cardiometabolic assessment. 
13. I relevantly miss some discussion about interventional proposals in the last paragraph 
of the Discussion. I would recommend to present or suggest some interventional approach 
since the study is now essentially based on a limited assessment perspective. 
Response: The Reviewer raises an important point about considering future interventional 
approaches that may help address the risk factors identified in the present study. We have 
expanded the last Discussion paragraph (page 19) to note that adjunctive, nonpharmacological 
behavioral interventions, specifically exercise and improved sleep, have the potential to improve 
DA function, cardiometabolic health, and neurocognitive function in the context of HIV.  
References 
14. There are mistakes in the citation style. 
Response: As suggested by the JAIDS author guidelines, we have set the EndNote reference style 
output to JAMA.  
Tables and Figures 
15. Table 1 should be properly presented in text. 
Response: We have added the following sentence to the Participants section of the Results: 
“Table 1 presents COMT group differences in demographic and clinical characteristics.” 
16, b in the legend of Table 1 seems not to represent the information indicated. 
Response: The information for superscript b represents the sample size for participants with 
available CSF viral load data. The superscript note is now written as: “bCSF viral load values 
available for a subset of participants: Met/Met (n=60), Val/Met (n=118),  Met/Met (n=82)” 
17. BDI score is displayed in Table 1 but later in legend it refers to BDI-II. 
Response: The correct abbreviation is BDI. We have corrected the legend accordingly. 
18. In Table 2 a reminder of the method for definition of neurocognitive impairment could 
be incorporated for an easier interpretation of the results. 
Response: Thank you for the suggestion. We have added an additional superscript to Table 2: 
“cNeurocognitive impairment defined as global deficit score  0.5” 
19. In Tables and Figures abbreviations and full words are indistinctly used; the same 
terms should be strictly used (e.g., Cardiometabolic risk score, CMRS, global deficit score, 
NCI, etc.). 
Response: We have updated Tables and Figures to ensure consistency across terms.  
 
 
Sincerely, 
 
 
 
Rowan Saloner, B.S. 
Predoctoral Research Fellow 
SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology 
HIV Neurobehavioral Research Program, University of California, San Diego 
220 Dickinson Street, Suite B, Mail Code 8231 
San Diego, CA 92103-8231 
Office: 619-543-5085 
 
 
 
Abstract 
Objective: The Val allele of the Val158Met single-nucleotide polymorphism of the 
catechol-o-methyltransferase gene (COMT) results in faster metabolism and reduced 
bioavailability of dopamine (DA). Among persons living with HIV (PLWH), Val carriers 
display neurocognitive deficits relative to Met carriers, presumably due to exacerbation 
of HIV-related depletion of DA. COMT may also impact neurocognition by modulating 
cardiometabolic function, which is often dysregulated among PLWH. We examined the 
interaction of COMT, cardiometabolic risk, and nadir CD4 on neurocognitive impairment 
(NCI) among HIV+ men.  
Methods: 329 HIV+ men underwent COMT genotyping and neurocognitive and 
neuromedical assessments. Cohort-standardized z-scores for body mass index, systolic 
blood pressure, glucose, triglycerides, and high-density lipoprotein cholesterol were 
averaged to derive a cardiometabolic risk score (CMRS). NCI was defined as 
demographically-adjusted global deficit score≥0.5. Logistic regression modelled NCI as 
a function of COMT, CMRS, and their interaction, covarying for estimated premorbid 
function, race/ethnicity, and HIV-specific characteristics. Follow-up analysis included the 
3-way interaction of COMT, CMRS, and nadir CD4.  
Results: Genotypes were 81 (24.6%) Met/Met, 147 (44.7%) Val/Met, and 101 (30.7%) 
Val/Val. COMT interacted with CMRS (p=0.02) such that higher CMRS increased risk of 
NCI among Val/Val (OR=2.13, p<.01), but not Val/Met (OR=0.93, p>.05) or Met/Met 
(OR=0.92, p>.05) carriers. Among Val/Val, nadir CD4 moderated the effect of CMRS 
(p<.01) such that higher CMRS increased likelihood of NCI only when nadir CD4<180.  
Abstract
Discussion: Results suggest a tripartite model by which genetically-driven low DA 
reserve, cardiometabolic dysfunction, and historical immunosuppression synergistically 
enhance risk of NCI among HIV+ men, possibly due to neuroinflammation and oxidative 
stress.   
Keywords: NeuroAIDS, Catechol O-Methyltransferase, HIV associated neurocognitive 
disorders, metabolic syndrome, dopamine, immunosuppression   
 
RUNNING HEAD: HIV, COMT, and Neurocognitive Impairment 1 
 
Body Word Count: 3742 
Abstract Word Count: 253 
Tables: 3 
Figures: 2 
 
COMT Val158Met Polymorphism, Cardiometabolic Risk, and Nadir CD4 Synergistically 
Increase Risk for Neurocognitive Impairment in Men Living with HIV 
 
Rowan Saloner, BS1,2, Maria J. Marquine, PhD2, Erin E. Sundermann, PhD2, Suzi Hong, 
PhD2, J. Allen McCutchan, MD3, Ronald J. Ellis, MD, PhD4, Robert K. Heaton, PhD2, 
Igor Grant, MD2, & Mariana Cherner, PhD2  
 
1San Diego State University/University of California, San Diego Joint Doctoral Program 
in Clinical Psychology, San Diego, California 
2Department of Psychiatry, University of California, San Diego 
3Department of Medicine, University of California, San Diego, La Jolla, California 
4Department of Neurosciences, University of California, San Diego, La Jolla, California 
 
Correspondence and Request for Reprints: 
Rowan Saloner, B.S. 
Predoctoral Research Fellow 
SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology 
University of California, San Diego, HIV Neurobehavioral Research Program 
220 Dickinson Street, Suite B, Mail Code 8231 
San Diego, CA 92103-8231 
Phone: 619-543-5085 
Fax: 619-543-1235 
rsaloner@ucsd.edu 
 
Conflicts of Interest and Source of Funding: This research was supported by the NIDA-
funded Translational Methamphetamine AIDS Research Center (TMARC) award 
P50DA026306 (PI: Igor Grant),  NIDA award R01DA026334 (PI: Mariana Cherner), and 
the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study awards 
N01MH22005, HHSN271201000036C, and HHSN271201000030C. R.S. is supported 
by NIAAA award T32AA013525 and M.J.M. is supported by NIMH award 
K23MH105297. The authors declare no conflicts of interest.  
 
Oral presentation delivered at the Interational Neuropsychological Society (INS) Annual 
Conference, New York, NY (2019, February).  
 
 
 
  
Manuscript Click here to
access/download;Manuscript;saloner_COMTxCMRS_main
RUNNING HEAD: HIV, COMT, and Neurocognitive Impairment 2 
Abstract 
Objective: The Val allele of the Val158Met single-nucleotide polymorphism of the 
catechol-o-methyltransferase gene (COMT) results in faster metabolism and reduced 
bioavailability of dopamine (DA). Among persons living with HIV (PLWH), Val carriers 
display neurocognitive deficits relative to Met carriers, presumably due to exacerbation 
of HIV-related depletion of DA. COMT may also impact neurocognition by modulating 
cardiometabolic function, which is often dysregulated among PLWH. We examined the 
interaction of COMT, cardiometabolic risk, and nadir CD4 on neurocognitive impairment 
(NCI) among HIV+ men.  
Methods: 329 HIV+ men underwent COMT genotyping and neurocognitive and 
neuromedical assessments. Cohort-standardized z-scores for body mass index, systolic 
blood pressure, glucose, triglycerides, and high-density lipoprotein cholesterol were 
averaged to derive a cardiometabolic risk score (CMRS). NCI was defined as 
demographically-adjusted global deficit score≥0.5. Logistic regression modelled NCI as 
a function of COMT, CMRS, and their interaction, covarying for estimated premorbid 
function, race/ethnicity, and HIV-specific characteristics. Follow-up analysis included the 
3-way interaction of COMT, CMRS, and nadir CD4.  
Results: Genotypes were 81 (24.6%) Met/Met, 147 (44.7%) Val/Met, and 101 (30.7%) 
Val/Val. COMT interacted with CMRS (p=0.02) such that higher CMRS increased risk of 
NCI among Val/Val (OR=2.13, p<.01), but not Val/Met (OR=0.93, p>.05) or Met/Met 
(OR=0.92, p>.05) carriers. Among Val/Val, nadir CD4 moderated the effect of CMRS 
(p<.01) such that higher CMRS increased likelihood of NCI only when nadir CD4<180.  
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Discussion: Results suggest a tripartite model by which genetically-driven low DA 
reserve, cardiometabolic dysfunction, and historical immunosuppression synergistically 
enhance risk of NCI among HIV+ men, possibly due to neuroinflammation and oxidative 
stress.   
Keywords: NeuroAIDS, Catechol O-Methyltransferase, HIV associated neurocognitive 
disorders, metabolic syndrome, dopamine, immunosuppression   
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Introduction 
Combination antiretroviral therapy (cART) prolongs life expectancies for persons 
living with HIV (PLWH); however, neurocognitive impairment (NCI) remains highly 
prevalent1,2. It is important to identify discrete neuropathological mechanisms that 
predict NCI in PLWH given that NCI can translate to negative and costly everyday 
functioning outcomes, including unemployment and poor cART adherence3,4. However, 
identifying these mechanisms has proven challenging5-7 because PLWH are a 
heterogeneous group whose neurocognition may be directly impacted by HIV, but also 
by comorbidities and genetic predispositions that enhance vulnerability to neural 
injury6,8,9.  
PLWH are at greater risk of cardiometabolic complications (i.e., hypertension, 
dyslipidemia, diabetes, and obesity) possibly due to HIV-related accelerated biological 
aging and iatrogenic consequences of cART10,11. Cardiometabolic risk contributes to 
NCI by triggering an array of neuro-compromising processes, including increased blood-
brain-barrier permeability, chronic inflammation, and endothelial dysfunction12-16. 
Furthermore, cardiometabolic risk factors predict imaging biomarkers of white matter 
and neurochemical abnormalities among PLWH17,18. While cardiometabolic risk factors 
increase risk of NCI in successfully treated PLWH, they are neither necessary nor 
sufficient to predict NCI. Thus, susceptibility to the contribution of cardiometabolic risks 
may be moderated by individual differences in resilience against HIV-related CNS 
dysfunction.  
One factor that could partially explain NCI among PLWH is dopamine (DA) 
bioavailability. HIV results in exposure to neurotoxic proteins Tat and gp120 that 
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damage frontostriatal regions rich in DA19,20. Post-mortem studies demonstrate 
decreased frontostriatal concentrations of DA and downregulated gene expression of 
DA receptors in HIV-infected versus HIV-uninfected persons, and that dysregulation of 
DA pathways relates to greater HIV disease severity (e.g., HIV RNA level, nadir CD4) 
and neurocognitive deficits among PLWH21-25.  
The erosion of DA homeostasis in PLWH has prompted research on catechol-o-
methyltransferase (COMT)6, a functionally diverse enzyme responsible for metabolism 
of DA, particularly in the prefrontal cortex (PFC). Neurons exposed to macrophage-
propagated HIV show increased mRNA expression of COMT and decreased expression 
of neuronal and synaptic proteins, suggesting that higher levels of COMT in HIV may 
contribute to DA and neurocognitive dysfunction. In further support of this theory, 
treatment of HIV-exposed neurons with a COMT inhibitor, Tolcapone, effectively 
reduced COMT expression and restored neuronal and synaptic integrity26. The 
Val158Met (rs4680) single nucleotide polymorphism (SNP) of the COMT gene encodes 
differential levels of COMT enzymatic activity, with the Met allele resulting in 40% less 
activity, and therefore greater DA bioavailability, than the Val allele27. The Met allele has 
been linked to enhanced neural activation and neurocognitive functioning in PLWH28,29, 
possibly due to resilience against HIV-related depletion of DA.  
Some literature suggests that COMT also operates within cardiometabolic 
pathways. COMT catalyzes the methylation of catechol estrogens into 2-
methoxyestradiol30, which reduces risk of diabetes, hypertension, and obesity31-34. 
However, COMT activity produces a precursor to homocysteine, which may increase 
risk of cardiovascular disease, and Val carriers have significantly higher blood levels of 
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total homocysteine than Met homozygotes35-37. Furthermore, lower central DA tone has 
been linked to obesity and markers of metabolic syndrome, and DA receptor 
neurotransmission is reduced in obese humans and animals38-40. While greater COMT 
activity associated with the Val allele may protect against cardiometabolic disorders 
through increased production of 2-methoxyestradiol, reduced COMT activity associated 
with the Met allele may also confer protection against cardiometabolic disorders by 
enhancing DA tone and limiting the accumulation of homocysteine. Although the 
influence of COMT on cardiometabolic health is complex, these mechanisms suggest 
that COMT may serve a multifactorial role in the neuropathogenesis of HIV-related NCI 
through the modulation of cardiometabolic risk and DA bioavailability.  
Our first aim is to examine the independent and interactive effects of COMT and 
cardiometabolic risk on NCI. Given the putative neuroprotective effect of the Met allele 
in PLWH, we hypothesize that Val/Val carriers with high cardiometabolic risk will have 
higher rates of NCI compared to others because they are most vulnerable to the 
deleterious impact of cardiometabolic risk factors on the brain. Because NCI has been 
more reliably linked to nadir versus current CD4 count in the cART era1,41-43, we will also 
examine the role of nadir CD4 in the conditional relationships between COMT, 
cardiometabolic risk, and NCI. We hypothesize that lower nadir CD4 counts will 
increase likelihood of NCI regardless of COMT and cardiometabolic risk, but will make a 
larger contribution to NCI in Val/Val carriers with high cardiometabolic risk.  
Methods 
Participants and Procedure 
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Participants were 329 HIV+ men who underwent COMT genotyping through NIH-
funded research studies coordinated by the HIV Neurobehavioral Research Program 
(HNRP) at the University of California, San Diego. Of the 329 participants, 76 were 
enrolled in the Translational Methamphetamine AIDS Research Center (TMARC), a 
NIDA-funded HNRP cohort study focusing on the central nervous system effects of HIV 
and methamphetamine. The other 253 participants were enrolled in the CNS HIV Anti-
Retroviral Therapy Effects Research (CHARTER) study. All studies were approved by 
local Human Subjects Protection Committees and all participants provided written 
informed consent. Exclusion criteria were: 1) diagnosis of psychotic or mood disorder 
with psychotic features, neurological or medical condition that may impair 
neurocognitive functioning, such as traumatic brain injury, stroke, epilepsy, hepatitis C, 
or advanced liver disease; 2) lifetime diagnosis of methamphetamine or cocaine use 
disorder; 3) low verbal IQ as estimated by a Wide Range Achievement Test44 (WRAT) 
reading subtest score <70; 4) evidence of intoxication by positive urine toxicology for 
illicit drugs (except marijuana) or Breathalyzer test for alcohol on the day of testing; and 
5) being female. We restricted our sample to men because sexually dimorphic effects of 
COMT on brain function have been reported45,46 and there were insufficient numbers of 
women participants in the parent studies to support separate analyses. Lifetime cocaine 
or methamphetamine use disorder, even remote, was exclusionary in order to eliminate 
potential confounding effects of stimulant-induced alteration of dopaminergic signaling.  
Neuromedical Assessment 
All participants underwent a comprehensive neuromedical assessment and non-
fasting blood draw. Detailed history of medical and antiretroviral (ARV) use was 
RUNNING HEAD: HIV, COMT, and Neurocognitive Impairment 8 
collected and ARV treatment status was coded as currently on, past use, or never used. 
HIV infection was diagnosed by enzyme-linked immunosorbent assay with Western blot 
confirmation. Routine clinical chemistry panels, complete blood counts, rapid plasma 
reagin, hepatitis C virus antibody, and CD4+ T cell count (flow cytometry) were 
performed at each site's certified clinical laboratory. HIV viral load in plasma and CSF 
were measured using reverse transcriptase-polymerase chain reaction (Amplicor, 
Roche Diagnostics, Indianapolis, IN), with a lower limit of quantitation (LLQ) of 50 
copies/ml). HIV viral load was dichotomized as detectable vs. undetectable at the LLQ 
of 50 copies/ml. 
Cardiometabolic Risk Assessment 
 Non-fasting levels of serum glucose, plasma triglycerides, and plasma total, high-
density lipoprotein (HDL)  and low-density lipoprotein (LDL) cholesterol levels were 
assayed by standard protocols at each site’s clinical laboratory. Blood pressure (BP) 
was measured in the seated position with an automated sphygmomanometer and body 
mass index (BMI) was calculated from measured weight and height. Our primary 
predictor of interest was a continuously scaled, composite cardiometabolic risk score 
(CMRS)47 based on the five components of metabolic syndrome outlined by the Adult 
Treatment Panel48 including obesity, elevated BP, elevate blood glucose, elevated 
triglycerides, and reduced (HDL) cholesterol. Cohort-standardized z-scores for BMI, 
systolic BP, glucose, triglycerides, and HDL cholesterol (inverse polarity) were averaged 
to generate our CMRS. A CMRS was derived from 4 of the 5 component z-scores for 
participants who were either missing HDL (n=50) or triglycerides (n=4) values.  
COMT Genotyping 
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 For participants enrolled in TMARC, DNA for genotyping was isolated from 
stored whole blood or peripheral blood mononuclear cells (PBMCs) using the Qiagen 
QIAamp DNA Mini Kit (Qiagen, Valencia, CA). COMT Val158Met (rs4680) SNP was 
assayed using an array that included SNPs associated with catecholaminergic genes49. 
For participants enrolled in CHARTER, DNA for genotyping was extracted from PBMCs 
using PUREGENE (Gentra Systems, Inc, Minneapolis, MN). All samples were 
genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0TM50. 
Neurocognitive Assessment 
 All participants completed a comprehensive and standardized neurocognitive 
assessment across seven neurocognitive domains commonly impacted by HIV1,51. Test 
scores were adjusted for known demographic influences (i.e., age, education, and 
race/ethnicity) on neurocognitive performance52-54. Deficit scores that give differential 
weight to impaired over normal performance were calculated for each domain and 
averaged to derive a global deficit score (GDS) ranging from 0 (normal) to 5 (severe). 
Consistent with prior studies, neurocognitive status was classified as impaired (NCI) vs. 
unimpaired using a validated cut-point of GDS  0.551,55 The GDS is easier to compute, 
more clearly operationalized (e.g., Frascati criteria do not specify how to apply a 1 SD 
cutoff to define “impairment” of ability domains with variable numbers of measures) and 
a more conservative approach to classifying NCI as compared to the clinical ratings 
algorithm used in Frascati criteria for HIV-associated Neurocognitive Disorders; 
however, an individual classified as impaired via GDS ≥ 0.5 is essentially guaranteed to 
meet the NCI aspect of Frascati criteria55.  
Psychiatric Assessment 
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 Current mood symptoms were assessed using the Beck Depression Inventory 
(BDI) version one or two56. The computer-based Composite International Diagnostic 
Interview (CIDI)57 was administered to determine DSM-IV diagnoses of current and 
lifetime substance use disorders (SUD) and Major Depressive Disorder (MDD).  
Statistical Analysis 
 COMT group differences in demographics, HIV disease, neuropsychiatric, 
cardiometabolic, and neurocognitive variables were examined using ANOVAs, Kruskal-
Wallis tests, and Chi-square statistics as appropriate. To follow-up on significant 
omnibus results, pair-wise comparisons were conducted using Tukey’s Honest 
Significant Difference (HSD) tests for continuous outcomes or Bonferroni-corrections for 
categorical outcomes58. Cohen’s d statistics are presented for estimates of effect size 
for statistically significant pair-wise differences. Logistic regression examined the 
univariate relationship between CMRS and NCI.  
 Next, we used multivariate logistic regression to model our NCI classification as a 
function of COMT, CMRS, and their interaction. COMT genotype was reference coded59 
with the high enzymatic activity Val/Val group as the reference. WRAT, race/ethnicity, 
nadir CD4, current CD4, plasma viral load detectability, and ARV status were entered 
as covariates because they either significantly differed across COMT genotype or are 
known to influence neurocognition in the cART era1,60. A 3-way interaction term 
between nadir CD4*COMT*CMRS, as well as accompanying lower-order terms, was 
added in a follow-up model in order to explore the potential moderating effect of HIV-
induced immunosuppression on the contributions of COMT and CMRS on NCI. Group 
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differences and logistic regression analyses were performed using JMP Pro version 
12.0.1 (JMP®, Version <12.0.1>, SAS Institute Inc., Cary, NC, 1989-2007). 
Exploratory analyses, stratified by COMT genotype, employed the Johnson-
Neyman (J-N) technique61,62 to compute any specific boundaries of nadir CD4 at which 
CMRS significantly predicted NCI. These boundaries are referred to as regions of 
significance. Compared to simple slope analyses that describe the effect of a predictor 
(i.e., CMRS) at fixed levels of a continuous moderator (i.e., nadir CD4), the J-N 
technique identifies the full range of moderator values for which the predictor slope is 
statistically significant. Region of significance analyses adjusted for false discovery 
rate63 and were computed using the jtools package in R statistical software (version 
3.4.4, R Foundation for Statistical Computing, Vienna, Austria).  
Results 
Participants  
 Table 1 presents COMT group differences on demographic and clinical 
characteristics. COMT distribution across the 329 participants (age: M=44.0, SD=8.97, 
education: M=14.1, SD=2.34) was 81 (24.6%) Met/Met, 147 (44.7%) Val/Met, and 101 
(30.7%) Val/Val. Genotype distribution was consistent with Hardy-Weinberg equilibrium 
in the full sample (𝜒2=3.49, p=0.06) and within each race/ethnicity group (ps>.11). 
However, genotype frequency differed significantly by race/ethnicity (𝜒2= 11.24, p=0.02) 
with non-Hispanic White participants more likely to carry a Met allele than non-Hispanic 
Black participants (𝜒2=8.75, p=0.003). COMT groups were comparable across most 
demographic, psychiatric, and HIV disease characteristics, with the exception of 
estimated premorbid verbal IQ for which Met/Met displayed significantly higher WRAT 
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scores than Val/Val (d=0.40, p=0.007). Most participants experienced cART-induced 
immune reconstitution, as evidenced by active ARV use (76%) and markedly higher 
current CD4 counts (median=458 cells/mm3) compared to nadir CD4 counts 
(median=180 cells/mm3). Half the sample (51%) had detectable levels of plasma viral 
RNA at a limit of detection of 50 copies per ml.   
COMT, Cardiometabolic Risk, and NCI 
 Table 2 presents COMT group differences on cardiometabolic and 
neurocognitive variables. Met/Met had significantly higher diastolic blood pressure than 
Val/Met (d=0.37, p=0.02) but not Val/Val. COMT groups did not differ significantly on 
any other cardiometabolic risk parameters, including the composite CMRS (F=0.09, 
p=0.91). Similarly, COMT groups did not differ significantly on GDS (F=0.17, p=0.84) or 
frequency of NCI (χ2=2.39, p=0.30), with rates ranging from 32% (Val/Met) to 42% 
(Val/Val). Although greater CMRS increased likelihood of NCI, this relationship was also 
not significant (OR=1.12, 95%CI [0.89-1.40], p=0.34).  
COMT and CMRS Interaction 
 Table 3 presents estimates for the multivariate logistic regression modelling NCI 
as a function of COMT, CMRS, and NCI, covarying for WRAT scores, race/ethnicity, 
and HIV disease characteristics. The overall model was significant (𝜒2(13,329)=392.68, 
p=0.001). A significant omnibus interaction between COMT and CMRS was detected 
(𝜒2(2,329)=7.93, p=0.02) such that higher CMRS levels significantly increased 
likelihood of NCI among Val/Val (OR=2.13, p<.01), yet the deleterious effect of CMRS 
on NCI was significantly attenuated in Met/Met (interaction of CMRS x Met/Met 
[compared to Val/Val]: ORR=0.42, p<.05) and Val/Met (interaction of CMRS x Val/Met 
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[compared to Val/Val]: ORR=0.43, p<.05). Specifically, CMRS did not significantly 
predict NCI among Met/Met (OR=0.92, p>.05) or Val/Met (OR=0.93, p>.05) carriers 
(Figure 1). Lower WRAT, lower nadir CD4, and detectable HIV RNA significantly 
increased probability of NCI (ps<.05).  
Conditional Role of Nadir CD4 
 To determine whether HIV disease severity influenced the interactive effects of 
COMT and CMRS on NCI, we expanded our model with terms capturing the 3-way 
interaction between nadir CD4, COMT, and CMRS. A significant 3-way interaction was 
detected between nadir CD4, COMT, and CMRS (𝜒2(2,329)=8.86, p=0.01). Nadir CD4 
did not significantly alter the null associations between CMRS and NCI among Val/Met 
and Met/Met. In Val/Val, nadir CD4 significantly moderated the deleterious effect of 
CMRS on NCI (for 50-unit increase: ORR=0.53, 95%CI [0.32, 0.81], p=0.008). In order 
to inspect changes in the slope of CMRS on NCI due to different nadir CD4 counts, we 
applied the J-N technique. In Val/Val, CMRS significantly increased likelihood of NCI 
(i.e., lower bound of CMRS slope>0) at nadir CD4 counts below 180 (Figure 2). 
Conversely, CMRS did not significantly predict NCI in Val/Val for nadir CD4 counts at or 
above 180.  
 To focus on a clinically relevant subgroup, we applied the 3-way interaction 
model in participants who were currently using cART and had undetectable HIV RNA 
(n=155). Results in this virologically suppressed subgroup did not differ from those in 
the entire study sample, with COMT, CMRS, and nadir CD4 significantly interacting to 
predict NCI (𝜒2(2,150)=10.25, p=0.006).  
Discussion 
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 Dopaminergic dysregulation, cardiometabolic dysfunction, and low nadir CD4 
counts (i.e., advanced HIV-induced immunosuppression) are putative risk factors for 
NCI in the context of HIV. In contrast to most neuroAIDS studies that examine 
independent effects of risk factors on NCI, this study also examined interactions of 
cardiometabolic risk, COMT, and nadir CD4 in order to address the complex interplay of 
these risk factors. Although neither COMT nor CMRS correlated univariably with NCI, 
higher CMRS significantly increased probability of NCI in Val/Val individuals. 
Furthermore, CMRS effects on neurocognitive function in Val/Val carriers were 
moderated by nadir CD4: higher CMRS increased probability of NCI only in participants 
with nadir CD4 counts below 180. These findings remained significant in patients with 
fully-suppressed HIV on cART, underscoring the relevance of these genetic and 
environmental risk factors for NCI for even the most successfully treated PLWH.  
 Our group has previously reported better executive function among Met/Met, 
compared to Val-carriers, in HIV+ men29. In contrast, the Multicenter AIDS Cohort Study 
found no main effects of COMT or interactive effects with stimulant use and current CD4 
on neurocognitive performance in predominantly male (87%-100%) samples64,65. In our 
study, COMT did not univariably relate to frequency of NCI, which, consistent with prior 
GDS-based estimates of NCI in PLWH51,55, was 36% across the entire study sample. 
We may not have detected a univariable relationship between COMT and NCI because 
individual SNPs often exhibit modest associations with behavioral phenotypes66. Given 
that COMT pleiotropically influences multiple neurobiological processes, the study of 
moderating environmental variables can help explain under which conditions the 
neurocognitive effects of COMT are most salient.  
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Our results support a gene x environment interaction approach, as the putatively 
harmful effect of the Val allele only appeared under environmental conditions of high 
cardiometabolic burden and low nadir CD4 counts. Similar interactive effects of COMT 
and cardiovascular risk have been previously reported in healthy adults, with Val 
carriers demonstrating steeper declines in episodic memory compared to Met/Met 
individuals only at elevated levels of pulse pressure67. While the effects of 
cardiometabolic comorbidities on poor neurocognition are not unique to PLWH, 
cardiometabolic abnormalities may be particularly disruptive in PLWH given their high 
prevalence and potential to combine with other HIV-related brain insults to 
synergistically deplete cognitive reserve68. Although studies of cardiometabolic risk 
often dichotomize individual cardiometabolic conditions based on thresholds of clinical 
laboratory values69, we modelled cardiometabolic risk as a standardized, continuous 
variable. This approach is statistically advantageous because continuous predictors 
preserve power and precision70. Moreover, thresholds for dichotomizing cardiometabolic 
conditions are imprecisely defined and overlook incremental relationships between 
cardiovascular disease outcomes (e.g., stroke) and health indicators (e.g., BP)71. 
Importantly, continuous cardiometabolic risk scores inversely relate to physical 
activity47,72 and therefore, provide further evidence to advocate exercise in its 
neurocognitive benefits for PLWH.  
With respect to conditional effects of HIV-induced immunosupression, Levine et 
al.65 did not detect interactions between current CD4 count and DA-related genes, 
including COMT, on neurocognitive performance. However, as the authors note, current 
CD4 may be a suboptimal indicator of HIV disease severity given that nadir CD4 is a 
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stronger predictor of NCI and brain integrity in the cART era1,41,73. Furthermore, lower 
nadir CD4, but not current CD4, is correlated with reduced DA transporter availability in 
the ventral striatum25. Our results indicating that lower nadir CD4 counts independently 
predict higher odds of NCI are consistent with the prior findings of Ellis et al.41 that 
describe a monotonic relationship between lower nadir CD4 counts and higher odds of 
NCI, even in PLWH with viral suppression and minimal-to-moderate comorbidity burden. 
Importantly, we also demonstrate that nadir CD4 moderates the interactive effects of 
COMT and CMRS. The clinical impact of these findings is highlighted by the substantial 
portion (55%) of Val/Val participants with nadir CD4 counts at or below 180, a range at 
which our region of significance analysis indicates a heightened vulnerability to the 
deleterious neurocognitive effects of cardiometabolic risk. In a prior investigation that 
implemented machine learning to generate predictive models for NCI, the predictive 
utility of viral load and duration of treatment were improved when nadir CD4 was less 
than 22574, a threshold similar to that of the present study.  
Some hypothesize that the relationship between cortical function and DA 
bioavailability follows an inverted U-shaped curve, with optimal neurocognition occurring 
at intermediate levels of DA signaling75,76. Within this framework, severe 
immunosuppression in PLWH may lead to persistently suboptimal levels of bioavailable 
DA even after successful immune reconstitution with cART. The slow rate of DA 
clearance conferred by the Met allele may protect against this shift, whereas the 
neurocognitive deficits present in Val/Val PLWH with high cardiometabolic burden may 
reflect an inability to compensate for reduced cognitive resources associated with DA 
dysfunction.  
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Although limitations in our data prevents us from investigating biological 
mechanisms that may underlie the interactive effects of COMT, CMRS, and nadir CD4 
on NCI, we offer several plausible neurobiological interpretations. Chronic 
neuroinflammation is a hallmark feature of HIV-related CNS dysfunction77. 
Immunosuppression, cardiovascular disease, and metabolic syndrome are associated 
with increased levels of pro-inflammatory biomarkers in the periphery and in CSF, as 
well as neuroinflammation on magnetic resonance spectroscopy in PLWH11,17,78-80. 
Limited bioavailability of DA and epinephrine due to high enzymatic activity of COMT 
may also result in poor neuroinflammatory regulation because catecholamines play a 
pivotal role in modulating lymphocyte and inflammasome activity81,82. In addition to 
neuroinflammatory dysregulation, excessive formation of reactive oxygen species and 
endothelial dysfunction are neurotoxic processes associated with immunosuppression, 
cardiometabolic risk, and catecholamine metabolism83-89. While our data reflect the 
neurobehavioral consequences of genetically-driven low DA signaling, poor 
cardiometabolic health, and more severe HIV disease, studies at a cellular level are 
needed to elucidate the mechanisms of their interactions.   
 We acknowledge several limitations to this study. First, the cross-sectional and 
associative nature of our data prevent us from drawing causal inferences, especially 
about the relationship between NCI and CMRS in the context of genetic and HIV 
disease history predictors. Second, we lacked an HIV- uninfected comparison group, 
hindering our ability to determine the specificity of our findings to PLWH. However, by 
exploring the conditional effect of nadir CD4 with the J-N technique, we demonstrate 
how HIV disease severity in a clinically-relevant and well-represented range (i.e., nadir 
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CD4 <180) can modulate the effects of genetic and environmental risk factors for NCI. 
Third, our results focused on clinically informative risk factors for NCI that may inform 
future interventions targeting the maintenance of cardiometabolic health (e.g., exercise, 
diet, sleep) and dopaminergic therapy (e.g., COMT-inhibitors), but our sample 
comprised men only and therefore limits the applicability of our findings to women. 
Fourth, we studied the effects of only one variant of COMT, but not other DA-related 
genetic variants on NCI in PLWH. As is the case with theoretically-driven single SNP 
analyses, COMT may be in linkage disequilibrium with other SNPs in the DA pathway 
that could account for the presumed effects of COMT. “Omics” techniques that leverage 
rich, multi-leveled data (e.g., genetic, transcriptomic, epigenetic) may advance the 
characterization of complex and subtle HIV-related neurobiological phenotypes6. Given 
that multiple components of the DA signaling pathway (e.g., receptors, metabolic 
enzymes, transporters) can be quantified across multiple levels of analysis (e.g., host 
genetics, microRNA expression, imaging), an “omics” approach has the potential to 
uncover clusters of DA-related factors that track with intermediate biological phenotypes 
as well as disease and neurobehavioral endpoints (e.g., NCI). 
 Taken together, our findings suggest a tripartite model by which genetically-
driven low DA reserve, cardiometabolic dysfunction, and history of immunosuppression 
synergistically enhance risk of NCI among HIV+ men. These interactive effects remain 
significant in virally suppressed participants receiving cART, suggesting that currently 
effective HIV treatment alone may not sufficiently mitigate neurocognitive dysfunction 
associated with the combination of genetic vulnerabilities, historically severe HIV-
induced immunosupression, and cardiometabolic risk factors. In addition to cART, 
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adjunctive behavioral therapies that target modifiable lifestyle factors could be 
considered as a means to address this diverse combination of risk factors90. In 
particular, interventions to increase physical activity and/or reduce sleep disturbances 
may help stabilize DA function and cardiometabolic health, reduce inflammatory and 
oxidative stress burden, and subsequently ameliorate persisting neurocognitive deficits 
in HIV-infected patients91-95.  
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Figure Captions 
 
Figure 1. Higher cardiometabolic risk scores significantly increase probability of 
neurocognitive impairment (NCI) in Val/Val participants (OR=2.13, p<.01), but do not 
relate to NCI in Val/Met (OR=0.93, p>0.05) or Met/Met (OR=0.92, p>0.05) participants.  
 
Figure 2. Effect sizes (logits) of cardiometabolic risk scores (CMRS) on neurocognitive 
impairment (NCI) are plotted across nadir CD4 count for the Val/Val group. When the X-
axis zero-line is included in the false discovery rate-adjusted confidence band, the effect 
of CMRS is not statistically significant at that nadir CD4 count. The region of 
significance occurs to the left of the dashed line, indicating that higher CMRS is 
significantly associated with greater likelihood of NCI only for nadir CD4 counts below 
180. 
 
Table 1. Demographic and clinical characteristics by COMT genotype (N=329) 
 
Variable 
Met/Met 
(n=81) 
Val/Met 
(n=147) 
Val/Val 
(n=101) 
 
p 
Demographics        
  Age (years) 45.1 (9.69) 43.7 (9.09) 43.6 (8.16) 0.44 
  Education (years) 14.3 (2.54) 14.1 (2.39) 13.9 (2.1) 0.54 
  Estimated Verbal IQ (WRAT) 104.4 (11.41) 101 (11.3) 99.8 (11.76) 0.02a 
  Ethnicity    0.02a 
    Non-Hispanic White (n=245) 66 (81%) 110 (75%) 69 (68%)  
    Non-Hispanic Black (n=33) 3 (4%) 12 (8%) 18 (18%)  
    Hispanic (n=51) 12 (15%) 25 (17%) 14 (14%)  
HIV Disease Characteristics     
  AIDS diagnosis 53 (65%) 89 (61%) 57 (56%) 0.47 
  Duration of HIV infection (years) 10.2 (7.83) 9.5 (6.44) 9.2 (6.3) 0.60 
  Current CD4 count (cells/mm3) 517 (255.5) 470 (261.1) 457 (261.5) 0.27 
  Nadir CD4 count (cells/mm3) 180 [63.5-305] 175 [44-297] 175 [55-297.5] 0.83 
  Plasma viral load     
    Copies/ml (log10) 1.8 [1.7-3.3] 1.9 [1.7-3.7] 2.3 [1.7-3.9] 0.45 
    Detectable 42 (52%) 69 (47%) 57 (56%) 0.33 
  CSF viral load     
    Copies/ml (log10)b 1.7 [1.7-1.7] 1.7 [1.7-2.2] 1.7 [1.7-2.4] 0.21 
    Detectableb 11 (18%) 34 (29%) 24 (29%) 0.24 
  ARV status    0.36 
    Currently on 67 (83%) 105 (71%) 77 (76%)  
    Past use only 7 (9%) 16 (11%) 10 (10%)  
    ARV naïve 7 (9%) 26 (18%) 14 (14%)  
  Current regimen type    0.21 
    PI-based 31 (46%) 54 (51%) 42 (55%)  
    NNRTI-based 27 (40%) 38 (36%) 30 (39%)  
    PI/NNRTI-based 4 (6%) 11 (10%) 5 (6%)  
    Other 5 (7%) 2 (2%) 0 (0%)  
  Duration of current regimen 
(months) 
12 [3-33] 13 [4-27] 12 [4-33] 0.96 
Neuropsychiatric characteristics     
  Lifetime any substance use 
disorder  
38 (47%) 68 (46%) 51 (51%) 0.80 
    Alcohol 35 (43%) 57 (38%) 42 (42%) 0.79 
    Cannabis 16 (20%) 21 (14%) 18 (18%) 0.54 
    Opioid 0 (0%) 1 (1%) 0 (0%) 0.99 
  Major Depressive Disorder      
    Lifetime 44 (54%) 72 (49%) 51 (51%) 0.74 
    Current 15 (19%) 19 (13%) 12 (12%) 0.41 
  BDI score 11.8 (9.57) 12.6 (10.14) 11.2 (9.32) 0.52 
Note. Values presented as mean (SD), median [IQR], or N (%). WRAT= Wide-Range 
Achievement reading subtest; ARV= antiretroviral therapy; PI= Protease-inhibitor; 
Tables
NNRTI= non-nucleoside reverse transcriptase inhibitor; BDI= Beck Depression 
Inventory  
aSignificant difference between Met/Met and Val/Val 
bCSF viral load values available for a subset of participants: Met/Met (n=60), Val/Met 
(n=118),  Met/Met (n=82) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Cardiometabolic risk and neurocognitive performance by COMT 
genotype  
 
Variable 
Met/Met 
(n=81) 
Val/Met 
(n=147) 
Val/Val 
(n=101) 
 
p 
Cardiometabolic parameters     
  Cardiometabolic risk score 0.01 (0.489) -0.02 (0.548) -0.01 (0.467) 0.91 
  Body mass index (kg/m2)a 26.3 (4.42) 25.8 (4.37) 25.4 (4.46) 0.43 
  Systolic blood pressure (mm Hg)a 127 (14.13) 124.4 (15.41) 124.6 (14.76) 0.41 
  Diastolic blood pressure (mm Hg)a  79.3 (9.68) 75.8 (8.98) 76.2 (9.66)  0.02b 
  Total cholesterol (mg/dL) 196.8 (54.11) 184.6 (40.68) 192.2 (41.24) 0.12 
  High-density lipoprotein (mg/dL)a 41.8 (15.94) 42.2 (15.71) 44.5 (22.52) 0.59 
  Low-density lipoprotein (mg/dL) 111.8 (37.63) 100.2 (35.16) 106.8 (35.22) 0.10 
  Triglycerides (mg/dL)a 217.6 (149.22) 221.3 (140.91) 228.8 (158.63) 0.87 
  Glucose (mg/dL)a 94 [86-105.5] 92 [81-107] 92 [83-107.5] 0.87 
Neurocognitive Performance     
  Global deficit score 0.51 (0.52) 0.49 (0.58) 0.47 (0.48) 0.84 
  Neurocognitive impairmentc 29 (36%) 47 (32%) 42 (42%) 0.30 
Note. Values presented as mean (SD), median [IQR], or N (%). 
aCardiometabolic risk score component 
bSignificant difference between Met/Met and Val/Met  
cNeurocognitive impairment defined as global deficit score  0.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Multivariable logistic regression predicting neurocognitive impairment 
Predictor B (SE) p ORa OR 95% CI 
Met/Metb -0.15 (0.34) 0.664 0.87 [0.45, 1.67] 
Val/Metb -0.42 (0.29) 0.156 0.66 [0.37, 1.17] 
Cardiometabolic risk scorec 0.76 (0.28) 0.007 2.13 [2.13, 3.68] 
Cardiometabolic risk score x Met/Met -0.87 (0.39) 0.025 0.42 [0.19, 0.90] 
Cardiometabolic risk score x Val/Met -0.83 (0.33) 0.012 0.43 [0.23, 0.83] 
WRATd -0.37 (0.11) 0.001 0.69 [0.55, 0.86] 
Nadir CD4e -0.13 (0.03) 0.017 0.88 [0.79, 0.98] 
Detectable plasma viral load 0.59 (0.29) 0.040 1.80 [1.03, 3.16] 
Current CD4e 0.03 (0.05) 0.338 1.05 [0.95, 1.11] 
ARV status never used -0.26 (0.47) 0.574 0.77 [0.31, 1.93] 
ARV status past usef 0.15 (0.44) 0.736 1.16 [0.49, 2.72] 
Non-Hispanic Blackg -0.37 (0.44) 0.398 0.69 [0.29, 1.63] 
Hispanich 0.30 (0.34) 0.374 1.36 [0.69, 2.64] 
Note. Bolded predictors are significant at p<.05. ARV= antiretroviral therapy; OR= odds 
ratio; WRAT= Wide Range Achievement Test 
aInteraction terms reflect odds rate ratios  
bCompared to Val/Val 
cPer 1 standard deviation change 
dPer 10-unit change 
ePer 50-unit change;   
fCompared to ARV status currently using 
gCompared to non-Hispanic White 
 
 
Figure 1. Greater cardiometabolic risk predicts neurocognitive impairment among 
Val/Val only 
 
 
 
Figure 1
Figure 2. Greater cardiometabolic risk significantly increases likelihood of 
neurocognitive impairment in Val/Val with nadir CD4 below 180 
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